Efficacy and patient-reported outcomes of a new mometasone cream treating atopic eczema

Skin Pharmacol Physiol. 2012;25(6):305-12. doi: 10.1159/000341809. Epub 2012 Aug 31.


This double-blind controlled phase II study was conducted to compare a newly developed formulation of mometasone furoate with a water content of 33% (Monovo® Cream) and with a smooth consistency versus the commercially available fatty cream of mometasone furoate (Ecural® Fettcreme) in terms of efficacy, cosmetic properties, and patients' acceptance. In 20 patients with mild to moderate atopic eczema, the preparations were tested intraindividually in a randomized mode and in two comparable lesion areas. Both preparations were equally effective and well tolerated. Due to improved cosmetic properties, the new formulation was preferred by the patients when asked for preferential use. Quality of life could be improved by treating with both preparations.

Trial registration: ClinicalTrials.gov NCT01119313.

Publication types

  • Clinical Trial, Phase II
  • Randomized Controlled Trial

MeSH terms

  • Administration, Topical
  • Adolescent
  • Dermatitis, Atopic / drug therapy*
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Mometasone Furoate
  • Pregnadienediols / administration & dosage*
  • Quality of Life
  • Self Report
  • Skin Cream / administration & dosage
  • Treatment Outcome


  • Pregnadienediols
  • Mometasone Furoate

Associated data

  • ClinicalTrials.gov/NCT01119313